Hepatitis
Commentary
Celebrity death finally solved – with locks of hair
Case: A 56-year-old musician presents with diffuse abdominal pain, cramping, and jaundice. His medical history is notable for years of diffuse...
From the Journals
CDC recommends screening all adults for hepatitis B
“Risk-based testing alone has not identified most persons living with chronic HBV infection and is considered inefficient for providers to...
Latest News
NICU use up, birth weights down in babies of mothers with HCV
New findings surprised a study researcher since the adverse outcomes weren’t related to prematurity.
Commentary
The five biggest changes in the 2023 adult vaccine schedules
COVID vaccines are now front and center among 2023’s five most important changes.
From the Journals
Strong support to provide DAA therapy to all patients with HCV
The findings highlight a “substantial need to provide DAA therapy to all patients with HCV, regardless of disease stage or financial status.”
Feature
Direct-acting antivirals tied to better outcomes in chronic Hep C
Researchers saw a significant reduction in all-cause mortality over a decade with direct-acting antivirals compared with no treatment.
Conference Coverage
A bold national plan to eliminate HCV by 2050
“We don’t get to use the ‘eliminate’ word all that often with a disease that’s taking thousands or tens of thousands – or worldwide, hundreds of...
Conference Coverage
Bepirovirsen: Is a ‘functional cure’ for HBV on the horizon?
“Bepirovirsen is just one RNA-based HBV therapy now being pursued. Several other antisense RNAs as well as the more malleable small interfering...
Conference Coverage
World falls short on HBV, HCV elimination targets
“As countries progress toward eliminating hepatitis B and C, we really need to do more to expand political will and financing of national...
News from the FDA/CDC
FDA expands tenofovir alafenamide (Vemlidy) use to adolescents with chronic HBV
The study met its primary endpoint of percentage of patients with HBV DNA levels less than 20 IU/mL at 24 weeks of therapy.
News
FDA rejects bulevirtide for hepatitis D
The FDA cited concerns over the production and delivery of bulevirtide, an investigational, first-in-class hepatitis delta virus entry-inhibitor...